source
- Sickle cell gene-editing therapy shows signs of revival as developers revisit trial after earlier safety haltA recent STAT+ article highlights that a sickle cell gene‑editing therapy, whose trial was stopped three years ago after a serious adverse event in the first patient, may be making a comeback. The…
- India proposes rule to instantly suspend drug manufacturing licenses that fail government quality testsIndia’s regulators have drafted new rules that would require an immediate suspension of any drug manufacturing license if the product does not meet quality standards in government testing. The prop…